Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Change in Account Payables: 2014-2025

Historic Change in Account Payables for CytomX Therapeutics (CTMX) over the last 11 years, with Sep 2025 value amounting to $419,000.

  • CytomX Therapeutics' Change in Account Payables fell 48.34% to $419,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$695,000, marking a year-over-year decrease of 90.93%. This contributed to the annual value of -$297,000 for FY2024, which is 79.17% up from last year.
  • CytomX Therapeutics' Change in Account Payables amounted to $419,000 in Q3 2025, which was up 955.10% from -$49,000 recorded in Q2 2025.
  • Over the past 5 years, CytomX Therapeutics' Change in Account Payables peaked at $3.3 million during Q3 2022, and registered a low of -$2.4 million during Q4 2022.
  • For the 3-year period, CytomX Therapeutics' Change in Account Payables averaged around -$196,091, with its median value being -$261,000 (2024).
  • In the last 5 years, CytomX Therapeutics' Change in Account Payables slumped by 661.54% in 2021 and then skyrocketed by 1,875.68% in 2022.
  • Over the past 5 years, CytomX Therapeutics' Change in Account Payables (Quarterly) stood at $1.2 million in 2021, then plummeted by 294.67% to -$2.4 million in 2022, then skyrocketed by 86.18% to -$328,000 in 2023, then climbed by 20.43% to -$261,000 in 2024, then slumped by 48.34% to $419,000 in 2025.
  • Its Change in Account Payables was $419,000 in Q3 2025, compared to -$49,000 in Q2 2025 and -$804,000 in Q1 2025.